Estimating prevalence of early symptomatic Alzheimer's disease in the United States
Open accessAbstract
INTRODUCTION: Understanding the prevalence of treatment‐eligible Alzheimer's disease (AD) is crucial for policy planning. METHODS: We used a comprehensive literature review and population cascade approach to estimate the number of amyloid‐positive, clinically diagnosed patients with mild cognitive impairment (MCI) or mild dementia due to AD in the United States. RESULTS: An estimated 666,646 individuals were identified as having MCI due to AD (range: 351,926–1,227,776) and 620,850 individuals as having mild dementia due to AD (range: 445,082–820,339). In a US population of 76 million individuals aged 60 or older in 2021, the estimates of MCI and mild dementia due to AD increased with age. CONCLUSIONS: As earlier diagnosis of AD and new disease‐modifying treatments become available, accurate population estimates are required to reduce uncertainty in the number of clinically diagnosed patients eligible for amyloid‐targeting therapies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Even fewer people living with MCI receive a diagnosis despite this being a stage where treatment and planning may be most effective.
“Even fewer people living with mild cognitive impairment (MCI), a precursor to dementia (see Overview), receive a diagnosis despite this being a stage where treatment and planning may be most effective.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [270]
The Results (Scenario results, page unavailable) estimate that 12.0% of people with MCI due to AD see a doctor, versus approximately 44.4% of those with mild dementia due to AD. The Discussion (Overall interpretation, page unavailable) says patients should be identified early to benefit from treatment. Seeing a doctor is not the same as receiving a diagnosis, however, and the paper does not establish that planning is most effective at the MCI stage; its estimates also concern MCI due to AD rather than all MCI. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 25 · Cited by 9
Research works printed but not linked: 2
- [8]Liu JL, Hlavka JP, Hillestad R, et al. Assessing the preparedness of the U.S. Health care system infrastructure for an Alzheimer's treatment. Rand Corporation. Available at: (accessed May 16, 2023) https://www.rand.org/pubs/research_reports/RR2272.html PMC6557037 31205802
- [29]Prados MJ, Liu Y, Jun H, Lam J, Mattke S. Projecting the long‐term societal value of a disease‐modifying treatment for Alzheimer's disease in the United States. Alzheimers Dement. 2022; 18(1): 142‐ 151. doi: 10.1002/alz.12578 35142025 PMC9303743 · DOI
- Authors
- Spargo, D., Zur, R., Lin, P., Synnott, P., Klein, E., & Hartry, A.
- Affiliations
- Eli Lilly (United States) (US)
- IQVIA (United States) (US)
- Tufts Medical Center (US)
- Corresponding author
- Spargo, Drew
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2023-10
- Volume
- 15
- Issue
- 4
- Pages
- e12497-e12497
- ISSN
- 2352-8729 (ISSN-L)
- PMC
- PMC10682565
- OpenAlex
- W4389095139
- Cited by
- 9
- References
- 25
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 1
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, prevalence estimation, mild cognitive impairment, mild dementia, amyloid-positive, anti-amyloid therapy, disease-modifying therapy, older adults, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
